Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women

NCT02753413 PHASE2 COMPLETED Results posted

The purpose of this study is to assess the safety and reactogenicity of a single intramuscular dose of GSK Biologicals' investigational RSV vaccine, in healthy, non-pregnant women aged 18 to 45 years.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	COMPLETED
Enrolment	102
Start date	Fri Apr 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Respiratory Syncytial Virus Infections

Interventions

• RSV vaccine GSK3003891A
• Boostrix

Countries

Belgium